A Phase 3 interventional study of Tirbanibulin ointment 1% in Keratosis, Actinic, sponsored by Almirall, S.A.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.
Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Keratosis, Actinic by Almirall, S.A. — none open to participants now, 1 under way, none of them phase 3. Keratosis, Actinic · Almirall, S.A..
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 in phase 3, and was the 10th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.
Browse Keratosis, Actinic studies →None of the 14 studies in Keratosis, Actinic by Almirall, S.A. is open now. The open studies under Keratosis, Actinic, anywhere →
Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 307 across the 12 interventional studies, 155 across the 2 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
1 of the studies in Keratosis, Actinic by Almirall, S.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387525Almirall, S.A.A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence in the TF of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of Actinic Keratosis (AK) lesions in the treatment field (TF) until completion of the response assessment period at Day 57.
Drug: Tirbanibulin ointment 1%
Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 5 were reported.
Time frame: Baseline, Day 5
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 8 were reported.
Time frame: Baseline, Day 8
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 15 were reported.
Time frame: Baseline, Day 15
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 29 were reported.
Time frame: Baseline, Day 29
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 57 were reported.
Time frame: Baseline, Day 57
Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)
Maximum local tolerability score post baseline was defined as the highest grade of any LSR reported at any post-baseline visits for a participant. Local tolerability score was assessed for signs erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. If a participant maximum individual sign local tolerability score stayed at 0 throughout the study, the participant was considered censored at last local tolerability score observation. Number of participants with maximum local tolerability score for each individual signs including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were reported.
Time frame: Baseline, Maximum post-baseline (up to Day 57)
Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration
Time to maximum local tolerability score (in days) for each individual sign was calculated as \[Date of first post-baseline occurrence of maximum local tolerability score for this individual sign - Date of first dose\]. If a participant maximum individual sign LTA score stays at 0 throughout the study, the participants was considered censored at their last LTA score observation. Maximum local tolerability score was assessed for each signs using a 4 - point scale of 0 - 3, where 0 = absent, 1= mild, 2= moderate and 3 = severe. The higher score indicates severe symptoms. Time to maximum local tolerability score for erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration was reported.
Time frame: Baseline up to Day 57
Local Tolerability Signs Total Composite Score by Visit at Day 5
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score assessed from baseline up to Day 5 was reported.
Time frame: Baseline, Day 5
Local Tolerability Signs Total Composite Score by Visit at Day 8
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 8 was reported.
Time frame: Baseline, Day 8
Local Tolerability Signs Total Composite Score by Visit at Day 15
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 15 was reported.
Time frame: Baseline, Day 15
Local Tolerability Signs Total Composite Score by Visit at Day 29
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 29 was reported.
Time frame: Baseline, Day 29
Local Tolerability Signs Total Composite Score by Visit at Day 57
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 57 was reported.
Time frame: Baseline, Day 57
Maximum Local Tolerability Signs Total Composite Score Post Baseline
The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Maximum local tolerability signs total composite score post baseline was reported.
Time frame: Baseline, Maximum post-baseline (up to Day 57)
Time to Maximum Local Tolerability Total Composite Score
Time to maximum composite local tolerability score (in days) was calculated as (Date of first post-baseline occurrence of maximum composite local tolerability score - Date of first dose). The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. If a participant's maximum composite local tolerability score stays at 0 throughout the study, the participant was considered censored at their last local tolerability score observation. Time to maximum local tolerability total composite score was reported.
Time frame: Baseline up to Day 57
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 5 was reported.
Time frame: Baseline, Day 5
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 8 was reported.
Time frame: Baseline, Day 8
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 15 was reported.
Time frame: Baseline, Day 15
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 29 was reported.
Time frame: Baseline, Day 29
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 57 was reported.
Time frame: Baseline, Day 57
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)
TEAEs were defined as either those adverse events (AEs) with an onset after dosing or those pre-existing conditions that worsened after dosing. An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An SAE with any untoward medical occurrence that at any dose, resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect in the child of a participant who was exposed to the study drug, or any other medically important event that may jeopardize the patient or require intervention to prevent one of the other outcomes. AESI's included in this study were skin cancers (including basal cell carcinoma, squamous cell carcinoma, and melanoma) based on their relevance for the current intended use. TEAEs included both serious and non-serious AEs.
Time frame: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Laboratory parameters included blood chemistry, hamatology, and urinalysis. Clinically significant laboratory abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in laboratory parameters (included hematology, blood chemistry and urinalysis) were reported.
Time frame: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinically significant vital signs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in vital signs were reported.
Time frame: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Physical Examination
Physical examination included weight and height measurements. Clinically significant physical examination abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in physical examination were reported.
Time frame: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Clinically significant ECGs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in ECG were reported.
Time frame: Baseline up to Day 57
This study was conducted at 20 sites in the United States from 28 June 2022 to 28 December 2022.
| Milestone | Tirbanibulin (Klisyri®) |
|---|---|
| Started | 105 |
| Completed | 102 |
| Not completed | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 1 |
| Withdrew: Physician decision | 1 |
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 5 were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Erythema — Grade 0 | 81 |
| Baseline: Erythema — Grade 1 | 19 |
| Baseline: Erythema — Grade 2 | 5 |
| Baseline: Erythema — Grade 3 | 0 |
| At Day 5: Erythema — Grade 0 | 13 |
| At Day 5: Erythema — Grade 1 | 41 |
| At Day 5: Erythema — Grade 2 | 44 |
| At Day 5: Erythema — Grade 3 | 3 |
| Baseline: Flaking/Scaling — Grade 0 | 84 |
| Baseline: Flaking/Scaling — Grade 1 | 17 |
| Baseline: Flaking/Scaling — Grade 2 | 4 |
| Baseline: Flaking/Scaling — Grade 3 | 0 |
| At Day 5: Flaking/Scaling — Grade 0 | 44 |
| At Day 5: Flaking/Scaling — Grade 1 | 38 |
| At Day 5: Flaking/Scaling — Grade 2 | 19 |
| At Day 5: Flaking/Scaling — Grade 3 | 0 |
| Baseline: Crusting — Grade 0 | 103 |
| Baseline: Crusting — Grade 1 | 2 |
| Baseline: Crusting — Grade 2 | 0 |
| Baseline: Crusting — Grade 3 | 0 |
| At Day 5: Crusting — Grade 0 | 90 |
| At Day 5: Crusting — Grade 1 | 9 |
| At Day 5: Crusting — Grade 2 | 2 |
| At Day 5: Crusting — Grade 3 | 0 |
| Baseline: Swelling — Grade 0 | 105 |
| Baseline: Swelling — Grade 1 | 0 |
| Baseline: Swelling — Grade 2 | 0 |
| Baseline: Swelling — Grade 3 | 0 |
| At Day 5: Swelling — Grade 0 | 73 |
| At Day 5: Swelling — Grade 1 | 25 |
| At Day 5: Swelling — Grade 2 | 3 |
| At Day 5: Swelling — Grade 3 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 0 | 105 |
| Baseline: Vesiculation/Pustulation — Grade 1 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 2 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 3 | 0 |
| At Day 5: Vesiculation/Pustulation — Grade 0 | 98 |
| At Day 5: Vesiculation/Pustulation — Grade 1 | 3 |
| At Day 5: Vesiculation/Pustulation — Grade 2 | 0 |
| At Day 5: Vesiculation/Pustulation — Grade 3 | 0 |
| Baseline: Erosion/Ulceration — Grade 0 | 105 |
| Baseline: Erosion/Ulceration — Grade 1 | 0 |
| Baseline: Erosion/Ulceration — Grade 2 | 0 |
| Baseline: Erosion/Ulceration — Grade 3 | 0 |
| At Day 5: Erosion/Ulceration — Grade 0 | 97 |
| At Day 5: Erosion/Ulceration — Grade 1 | 4 |
| At Day 5: Erosion/Ulceration — Grade 2 | 0 |
| At Day 5: Erosion/Ulceration — Grade 3 | 0 |
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 8 were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Erythema — Grade 0 | 81 |
| Baseline: Erythema — Grade 1 | 19 |
| Baseline: Erythema — Grade 2 | 5 |
| Baseline: Erythema — Grade 3 | 0 |
| At Day 8: Erythema — Grade 0 | 9 |
| At Day 8: Erythema — Grade 1 | 32 |
| At Day 8: Erythema — Grade 2 | 57 |
| At Day 8: Erythema — Grade 3 | 4 |
| Baseline: Flaking/Scaling — Grade 0 | 84 |
| Baseline: Flaking/Scaling — Grade 1 | 17 |
| Baseline: Flaking/Scaling — Grade 2 | 4 |
| Baseline: Flaking/Scaling — Grade 3 | 0 |
| At Day 8: Flaking/Scaling — Grade 0 | 18 |
| At Day 8: Flaking/Scaling — Grade 1 | 43 |
| At Day 8: Flaking/Scaling — Grade 2 | 33 |
| At Day 8: Flaking/Scaling — Grade 3 | 8 |
| Baseline: Crusting — Grade 0 | 103 |
| Baseline: Crusting — Grade 1 | 2 |
| Baseline: Crusting — Grade 2 | 0 |
| Baseline: Crusting — Grade 3 | 0 |
| At Day 8: Crusting — Grade 0 | 66 |
| At Day 8: Crusting — Grade 1 | 28 |
| At Day 8: Crusting — Grade 2 | 8 |
| At Day 8: Crusting — Grade 3 | 0 |
| Baseline: Swelling — Grade 0 | 105 |
| Baseline: Swelling — Grade 1 | 0 |
| Baseline: Swelling — Grade 2 | 0 |
| Baseline: Swelling — Grade 3 | 0 |
| At Day 8: Swelling — Grade 0 | 75 |
| At Day 8: Swelling — Grade 1 | 19 |
| At Day 8: Swelling — Grade 2 | 8 |
| At Day 8: Swelling — Grade 3 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 0 | 105 |
| Baseline: Vesiculation/Pustulation — Grade 1 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 2 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 3 | 0 |
| At Day 8: Vesiculation/Pustulation — Grade 0 | 101 |
| At Day 8: Vesiculation/Pustulation — Grade 1 | 1 |
| At Day 8: Vesiculation/Pustulation — Grade 2 | 0 |
| At Day 8: Vesiculation/Pustulation — Grade 3 | 0 |
| Baseline: Erosion/Ulceration — Grade 0 | 105 |
| Baseline: Erosion/Ulceration — Grade 1 | 0 |
| Baseline: Erosion/Ulceration — Grade 2 | 0 |
| Baseline: Erosion/Ulceration — Grade 3 | 0 |
| At Day 8: Erosion/Ulceration — Grade 0 | 91 |
| At Day 8: Erosion/Ulceration — Grade 1 | 8 |
| At Day 8: Erosion/Ulceration — Grade 2 | 3 |
| At Day 8: Erosion/Ulceration — Grade 3 | 0 |
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 15 were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Erythema — Grade 0 | 81 |
| Baseline: Erythema — Grade 1 | 19 |
| Baseline: Erythema — Grade 2 | 5 |
| Baseline: Erythema — Grade 3 | 0 |
| At Day 15: Erythema — Grade 0 | 33 |
| At Day 15: Erythema — Grade 1 | 61 |
| At Day 15: Erythema — Grade 2 | 7 |
| At Day 15: Erythema — Grade 3 | 0 |
| Baseline: Flaking/Scaling — Grade 0 | 84 |
| Baseline: Flaking/Scaling — Grade 1 | 17 |
| Baseline: Flaking/Scaling — Grade 2 | 4 |
| Baseline: Flaking/Scaling — Grade 3 | 0 |
| At Day 15: Flaking/Scaling — Grade 0 | 54 |
| At Day 15: Flaking/Scaling — Grade 1 | 33 |
| At Day 15: Flaking/Scaling — Grade 2 | 13 |
| At Day 15: Flaking/Scaling — Grade 3 | 1 |
| Baseline: Crusting — Grade 0 | 103 |
| Baseline: Crusting — Grade 1 | 2 |
| Baseline: Crusting — Grade 2 | 0 |
| Baseline: Crusting — Grade 3 | 0 |
| At Day 15: Crusting — Grade 0 | 86 |
| At Day 15: Crusting — Grade 1 | 12 |
| At Day 15: Crusting — Grade 2 | 3 |
| At Day 15: Crusting — Grade 3 | 0 |
| Baseline: Swelling — Grade 0 | 105 |
| Baseline: Swelling — Grade 1 | 0 |
| Baseline: Swelling — Grade 2 | 0 |
| Baseline: Swelling — Grade 3 | 0 |
| At Day 15: Swelling — Grade 0 | 96 |
| At Day 15: Swelling — Grade 1 | 4 |
| At Day 15: Swelling — Grade 2 | 1 |
| At Day 15: Swelling — Grade 3 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 0 | 105 |
| Baseline: Vesiculation/Pustulation — Grade 1 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 2 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 3 | 0 |
| At Day 15: Vesiculation/Pustulation — Grade 0 | 101 |
| At Day 15: Vesiculation/Pustulation — Grade 1 | 0 |
| At Day 15: Vesiculation/Pustulation — Grade 2 | 0 |
| At Day 15: Vesiculation/Pustulation — Grade 3 | 0 |
| Baseline: Erosion/Ulceration — Grade 0 | 105 |
| Baseline: Erosion/Ulceration — Grade 1 | 0 |
| Baseline: Erosion/Ulceration — Grade 2 | 0 |
| Baseline: Erosion/Ulceration — Grade 3 | 0 |
| At Day 15: Erosion/Ulceration — Grade 0 | 100 |
| At Day 15: Erosion/Ulceration — Grade 1 | 0 |
| At Day 15: Erosion/Ulceration — Grade 2 | 1 |
| At Day 15: Erosion/Ulceration — Grade 3 | 0 |
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 29 were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Erythema — Grade 0 | 81 |
| Baseline: Erythema — Grade 1 | 19 |
| Baseline: Erythema — Grade 2 | 5 |
| Baseline: Erythema — Grade 3 | 0 |
| At Day 29: Erythema — Grade 0 | 74 |
| At Day 29: Erythema — Grade 1 | 26 |
| At Day 29: Erythema — Grade 2 | 0 |
| At Day 29: Erythema — Grade 3 | 0 |
| Baseline: Flaking/Scaling — Grade 0 | 84 |
| Baseline: Flaking/Scaling — Grade 1 | 17 |
| Baseline: Flaking/Scaling — Grade 2 | 4 |
| Baseline: Flaking/Scaling — Grade 3 | 0 |
| At Day 29: Flaking/Scaling — Grade 0 | 84 |
| At Day 29: Flaking/Scaling — Grade 1 | 16 |
| At Day 29: Flaking/Scaling — Grade 2 | 0 |
| At Day 29: Flaking/Scaling — Grade 3 | 0 |
| Baseline: Crusting — Grade 0 | 103 |
| Baseline: Crusting — Grade 1 | 2 |
| Baseline: Crusting — Grade 2 | 0 |
| Baseline: Crusting — Grade 3 | 0 |
| At Day 29: Crusting — Grade 0 | 97 |
| At Day 29: Crusting — Grade 1 | 3 |
| At Day 29: Crusting — Grade 2 | 0 |
| At Day 29: Crusting — Grade 3 | 0 |
| Baseline: Swelling — Grade 0 | 105 |
| Baseline: Swelling — Grade 1 | 0 |
| Baseline: Swelling — Grade 2 | 0 |
| Baseline: Swelling — Grade 3 | 0 |
| At Day 29: Swelling — Grade 0 | 98 |
| At Day 29: Swelling — Grade 1 | 2 |
| At Day 29: Swelling — Grade 2 | 0 |
| At Day 29: Swelling — Grade 3 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 0 | 105 |
| Baseline: Vesiculation/Pustulation — Grade 1 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 2 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 3 | 0 |
| At Day 29: Vesiculation/Pustulation — Grade 0 | 100 |
| At Day 29: Vesiculation/Pustulation — Grade 1 | 0 |
| At Day 29: Vesiculation/Pustulation — Grade 2 | 0 |
| At Day 29: Vesiculation/Pustulation — Grade 3 | 0 |
| Baseline: Erosion/Ulceration — Grade 0 | 105 |
| Baseline: Erosion/Ulceration — Grade 1 | 0 |
| Baseline: Erosion/Ulceration — Grade 2 | 0 |
| Baseline: Erosion/Ulceration — Grade 3 | 0 |
| At Day 29: Erosion/Ulceration — Grade 0 | 100 |
| At Day 29: Erosion/Ulceration — Grade 1 | 0 |
| At Day 29: Erosion/Ulceration — Grade 2 | 0 |
| At Day 29: Erosion/Ulceration — Grade 3 | 0 |
Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 57 were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Erythema — Grade 0 | 81 |
| Baseline: Erythema — Grade 1 | 19 |
| Baseline: Erythema — Grade 2 | 5 |
| Baseline: Erythema — Grade 3 | 0 |
| At Day 57: Erythema — Grade 0 | 95 |
| At Day 57: Erythema — Grade 1 | 7 |
| At Day 57: Erythema — Grade 2 | 0 |
| At Day 57: Erythema — Grade 3 | 0 |
| Baseline: Flaking/Scaling — Grade 0 | 84 |
| Baseline: Flaking/Scaling — Grade 1 | 17 |
| Baseline: Flaking/Scaling — Grade 2 | 4 |
| Baseline: Flaking/Scaling — Grade 3 | 0 |
| At Day 57: Flaking/Scaling — Grade 0 | 99 |
| At Day 57: Flaking/Scaling — Grade 1 | 3 |
| At Day 57: Flaking/Scaling — Grade 2 | 0 |
| At Day 57: Flaking/Scaling — Grade 3 | 0 |
| Baseline: Crusting — Grade 0 | 103 |
| Baseline: Crusting — Grade 1 | 2 |
| Baseline: Crusting — Grade 2 | 0 |
| Baseline: Crusting — Grade 3 | 0 |
| At Day 57: Crusting — Grade 0 | 102 |
| At Day 57: Crusting — Grade 1 | 0 |
| At Day 57: Crusting — Grade 2 | 0 |
| At Day 57: Crusting — Grade 3 | 0 |
| Baseline: Swelling — Grade 0 | 105 |
| Baseline: Swelling — Grade 1 | 0 |
| Baseline: Swelling — Grade 2 | 0 |
| Baseline: Swelling — Grade 3 | 0 |
| At Day 57: Swelling — Grade 0 | 102 |
| At Day 57: Swelling — Grade 1 | 0 |
| At Day 57: Swelling — Grade 2 | 0 |
| At Day 57: Swelling — Grade 3 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 0 | 105 |
| Baseline: Vesiculation/Pustulation — Grade 1 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 2 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 3 | 0 |
| At Day 57: Vesiculation/Pustulation — Grade 0 | 102 |
| At Day 57: Vesiculation/Pustulation — Grade 1 | 0 |
| At Day 57: Vesiculation/Pustulation — Grade 2 | 0 |
| At Day 57: Vesiculation/Pustulation — Grade 3 | 0 |
| Baseline: Erosion/Ulceration — Grade 0 | 105 |
| Baseline: Erosion/Ulceration — Grade 1 | 0 |
| Baseline: Erosion/Ulceration — Grade 2 | 0 |
| Baseline: Erosion/Ulceration — Grade 3 | 0 |
| At Day 57: Erosion/Ulceration — Grade 0 | 102 |
| At Day 57: Erosion/Ulceration — Grade 1 | 0 |
| At Day 57: Erosion/Ulceration — Grade 2 | 0 |
| At Day 57: Erosion/Ulceration — Grade 3 | 0 |
Maximum local tolerability score post baseline was defined as the highest grade of any LSR reported at any post-baseline visits for a participant. Local tolerability score was assessed for signs erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. If a participant maximum individual sign local tolerability score stayed at 0 throughout the study, the participant was considered censored at last local tolerability score observation. Number of participants with maximum local tolerability score for each individual signs including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Erythema — Grade 0 | 81 |
| Baseline: Erythema — Grade 1 | 19 |
| Baseline: Erythema — Grade 2 | 5 |
| Baseline: Erythema — Grade 3 | 0 |
| At Maximum post-baseline (up to Day 57): Erythema — Grade 0 | 4 |
| At Maximum post-baseline (up to Day 57): Erythema — Grade 1 | 27 |
| At Maximum post-baseline (up to Day 57): Erythema — Grade 2 | 66 |
| At Maximum post-baseline (up to Day 57): Erythema — Grade 3 | 6 |
| Baseline: Flaking/Scaling — Grade 0 | 84 |
| Baseline: Flaking/Scaling — Grade 1 | 17 |
| Baseline: Flaking/Scaling — Grade 2 | 4 |
| Baseline: Flaking/Scaling — Grade 3 | 0 |
| At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 0 | 16 |
| At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 1 | 34 |
| At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 2 | 44 |
| At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 3 | 9 |
| Baseline: Crusting — Grade 0 | 103 |
| Baseline: Crusting — Grade 1 | 2 |
| Baseline: Crusting — Grade 2 | 0 |
| Baseline: Crusting — Grade 3 | 0 |
| At Maximum post-baseline (up to Day 57): Crusting — Grade 0 | 58 |
| At Maximum post-baseline (up to Day 57): Crusting — Grade 1 | 34 |
| At Maximum post-baseline (up to Day 57): Crusting — Grade 2 | 11 |
| At Maximum post-baseline (up to Day 57): Crusting — Grade 3 | 0 |
| Baseline: Swelling — Grade 0 | 105 |
| Baseline: Swelling — Grade 1 | 0 |
| Baseline: Swelling — Grade 2 | 0 |
| Baseline: Swelling — Grade 3 | 0 |
| At Maximum post-baseline (up to Day 57): Swelling — Grade 0 | 64 |
| At Maximum post-baseline (up to Day 57): Swelling — Grade 1 | 28 |
| At Maximum post-baseline (up to Day 57): Swelling — Grade 2 | 11 |
| At Maximum post-baseline (up to Day 57): Swelling — Grade 3 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 0 | 105 |
| Baseline: Vesiculation/Pustulation — Grade 1 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 2 | 0 |
| Baseline: Vesiculation/Pustulation — Grade 3 | 0 |
| At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 0 | 99 |
| At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 1 | 4 |
| At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 2 | 0 |
| At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 3 | 0 |
| Baseline: Erosion/Ulceration — Grade 0 | 105 |
| Baseline: Erosion/Ulceration — Grade 1 | 0 |
| Baseline: Erosion/Ulceration — Grade 2 | 0 |
| Baseline: Erosion/Ulceration — Grade 3 | 0 |
| At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 0 | 90 |
| At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 1 | 9 |
| At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 2 | 4 |
| At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 3 | 0 |
Time to maximum local tolerability score (in days) for each individual sign was calculated as \[Date of first post-baseline occurrence of maximum local tolerability score for this individual sign - Date of first dose\]. If a participant maximum individual sign LTA score stays at 0 throughout the study, the participants was considered censored at their last LTA score observation. Maximum local tolerability score was assessed for each signs using a 4 - point scale of 0 - 3, where 0 = absent, 1= mild, 2= moderate and 3 = severe. The higher score indicates severe symptoms. Time to maximum local tolerability score for erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration was reported.
| Days | Tirbanibulin (Klisyri®) |
|---|---|
| Erythema | 4.0 (4 to 14) |
| Flaking/Scaling | 7.0 (4 to 15) |
| Crusting | 7.0 (4 to 28) |
| Swelling | 4.0 (4 to 12) |
| Vesiculation/Pustulation | 4.0 (4 to 7) |
| Erosion/Ulceration | 7.0 (4 to 14) |
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score assessed from baseline up to Day 5 was reported.
| Score on a scale | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline | 0.5 ± 1.06 |
| At Day 5 | 2.6 ± 1.67 |
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 8 was reported.
| Score on a Scale | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline | 0.5 ± 1.06 |
| At Day 8 | 3.8 ± 2.25 |
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 15 was reported.
| Score on a Scale | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline | 0.5 ± 1.06 |
| At Day 15 | 1.6 ± 1.46 |
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 29 was reported.
| Score on a Scale | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline | 0.5 ± 1.06 |
| At Day 29 | 0.5 ± 0.80 |
Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 57 was reported.
| Score on a Scale | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline | 0.5 ± 1.06 |
| At Day 57 | 0.1 ± 0.36 |
The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Maximum local tolerability signs total composite score post baseline was reported.
| Score on a scale | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline | 0.5 ± 1.06 |
| At Maximum post-baseline (up to Day 57) | 4.1 ± 2.12 |
Time to maximum composite local tolerability score (in days) was calculated as (Date of first post-baseline occurrence of maximum composite local tolerability score - Date of first dose). The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. If a participant's maximum composite local tolerability score stays at 0 throughout the study, the participant was considered censored at their last local tolerability score observation. Time to maximum local tolerability total composite score was reported.
| Days | Tirbanibulin (Klisyri®) |
|---|---|
| Time to Maximum Local Tolerability Total Composite Score | 7.0 (6.01 to 7.31) |
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 5 was reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Hypopigmentation Presence | 22 |
| Baseline: Hypopigmentation Absence | 83 |
| At Day 5: Hypopigmentation Presence | 22 |
| At Day 5: Hypopigmentation Absence | 78 |
| Baseline: Hyperpigmentation Presence | 28 |
| Baseline: Hyperpigmentation Absence | 77 |
| At Day 5: Hyperpigmentation Presence | 26 |
| At Day 5: Hyperpigmentation Absence | 74 |
| Baseline: Scarring Presence | 12 |
| Baseline: Scarring Absence | 93 |
| At Day 5: Scarring Presence | 12 |
| At Day 5: Scarring Absence | 88 |
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 8 was reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Hypopigmentation Presence | 22 |
| Baseline: Hypopigmentation Absence | 83 |
| At Day 8: Hypopigmentation Presence | 21 |
| At Day 8: Hypopigmentation Absence | 80 |
| Baseline: Hyperpigmentation Presence | 28 |
| Baseline: Hyperpigmentation Absence | 77 |
| At Day 8: Hyperpigmentation Presence | 23 |
| At Day 8: Hyperpigmentation Absence | 78 |
| Baseline: Scarring Presence | 12 |
| Baseline: Scarring Absence | 93 |
| At Day 8: Scarring Presence | 13 |
| At Day 8: Scarring Absence | 88 |
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 15 was reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Hypopigmentation Presence | 22 |
| Baseline: Hypopigmentation Absence | 83 |
| At Day 15: Hypopigmentation Presence | 21 |
| At Day 15: Hypopigmentation Absence | 80 |
| Baseline: Hyperpigmentation Presence | 28 |
| Baseline: Hyperpigmentation Absence | 77 |
| At Day 15: Hyperpigmentation Presence | 20 |
| At Day 15: Hyperpigmentation Absence | 81 |
| Baseline: Scarring Presence | 12 |
| Baseline: Scarring Absence | 93 |
| At Day 15: Scarring Presence | 11 |
| At Day 15: Scarring Absence | 90 |
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 29 was reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Hypopigmentation Presence | 22 |
| Baseline: Hypopigmentation Absence | 83 |
| At Day 29: Hypopigmentation Presence | 20 |
| At Day 29: Hypopigmentation Absence | 80 |
| Baseline: Hyperpigmentation Presence | 28 |
| Baseline: Hyperpigmentation Absence | 77 |
| At Day 29: Hyperpigmentation Presence | 16 |
| At Day 29: Hyperpigmentation Absence | 84 |
| Baseline: Scarring Presence | 12 |
| Baseline: Scarring Absence | 93 |
| At Day 29: Scarring Presence | 10 |
| At Day 29: Scarring Absence | 90 |
Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 57 was reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Baseline: Hypopigmentation Presence | 22 |
| Baseline: Hypopigmentation Absence | 83 |
| At Day 57: Hypopigmentation Presence | 18 |
| At Day 57: Hypopigmentation Absence | 84 |
| Baseline: Hyperpigmentation Presence | 28 |
| Baseline: Hyperpigmentation Absence | 77 |
| At Day 57: Hyperpigmentation Presence | 16 |
| At Day 57: Hyperpigmentation Absence | 86 |
| Baseline: Scarring Presence | 12 |
| Baseline: Scarring Absence | 93 |
| At Day 57: Scarring Presence | 9 |
| At Day 57: Scarring Absence | 93 |
TEAEs were defined as either those adverse events (AEs) with an onset after dosing or those pre-existing conditions that worsened after dosing. An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An SAE with any untoward medical occurrence that at any dose, resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect in the child of a participant who was exposed to the study drug, or any other medically important event that may jeopardize the patient or require intervention to prevent one of the other outcomes. AESI's included in this study were skin cancers (including basal cell carcinoma, squamous cell carcinoma, and melanoma) based on their relevance for the current intended use. TEAEs included both serious and non-serious AEs.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Participants with TEAEs | 29 |
| Participants with Serious TEAEs | 2 |
| Participants with AESIs | 2 |
Laboratory parameters included blood chemistry, hamatology, and urinalysis. Clinically significant laboratory abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in laboratory parameters (included hematology, blood chemistry and urinalysis) were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | 0 |
Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinically significant vital signs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in vital signs were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | 1 |
Physical examination included weight and height measurements. Clinically significant physical examination abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in physical examination were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Physical Examination | 1 |
ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Clinically significant ECGs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in ECG were reported.
| Participants | Tirbanibulin (Klisyri®) |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) | 1 |
Collected over Baseline up to Day 57. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirbanibulin (Klisyri®) | 1/105 (1%) | 2/105 (1.9%) | 29/105 (27.6%) |
| Event | Tirbanibulin (Klisyri®) |
|---|---|
| TachycardiaCardiac disorders | 1/105 |
| AstheniaGeneral disorders | 1/105 |
| Failure to thriveMetabolism and nutrition disorders | 1/105 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/105 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/105 |
| EncephalopathyNervous system disorders | 1/105 |
| Acute kidney injuryRenal and urinary disorders | 1/105 |
| Event | Tirbanibulin (Klisyri®) |
|---|---|
| Application site pruritusGeneral disorders | 11/105 |
| Application site painGeneral disorders | 9/105 |
| DizzinessNervous system disorders | 2/105 |
| ParaesthesiaNervous system disorders | 2/105 |
| Atrial fibrillationCardiac disorders | 1/105 |
| Application site bruiseGeneral disorders | 1/105 |
| Application site drynessGeneral disorders | 1/105 |
| Application site hypoaesthesiaGeneral disorders | 1/105 |
| Oedema peripheralGeneral disorders | 1/105 |
| TendernessGeneral disorders | 1/105 |
The safety population included all enrolled participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Tirbanibulin (Klisyri®) |
|---|---|
| Mean | 69.1 ± 8.90 |
| Sex: Female, Male(Participants) | Tirbanibulin (Klisyri®) |
|---|---|
| Female | 33 |
| Male | 72 |
| Ethnicity (NIH/OMB)(Participants) | Tirbanibulin (Klisyri®) |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 98 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Tirbanibulin (Klisyri®) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 105 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Number of AK lesions at baseline(Number of AK lesions) | Tirbanibulin (Klisyri®) |
|---|---|
| Mean | 7.7 ± 2.72 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Dec 2022, 6 months.
Results were first posted in Jan 2024, 1 year after primary completion.
Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirbanibulin